Global Venous Leg Ulcers (Crural ulcer) Drugs Development Research Report 2022: Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

Global Venous Leg Ulcers (Crural ulcer) Drugs Development Research Report 2022: Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com




Global Venous Leg Ulcers (Crural ulcer) Drugs Development Research Report 2022: Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Venous Leg Ulcers (Crural ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.

This pipeline guide Venous Leg Ulcers (Crural ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural Ulcer) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural Ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Unknown stages are 1, 10, 2, 4 and 1 respectively.

Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural Ulcer) (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural Ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Venous Leg Ulcers (Crural Ulcer) (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Venous Leg Ulcers (Crural Ulcer) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural Ulcer) (Dermatology)

Key Topics Covered:

Introduction

Report Coverage

Overview

Therapeutics Development

  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies

Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Companies Involved in Therapeutics Development

  • Aurealis Therapeutics AG
  • CytoTools AG
  • Energenesis Biomedical Co Ltd
  • GangaGen Biotechnologies Pvt Ltd
  • Hypo-Stream Ltd
  • Mallinckrodt Plc
  • MediWound Ltd
  • NovaLead Pharma Pvt Ltd
  • Promore Pharma AB
  • QBiotics Group Ltd
  • Reponex Pharmaceuticals AS
  • RHEACELL GmbH & Co KG
  • Tissue Repair Pty Ltd
  • Venturis Therapeutics Inc
  • Zhittya Genesis Medicine Inc

Drug Profiles

  • Amesanar – Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • AUP-16 – Drug Profile
  • Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers – Drug Profile
  • CVBT-141 – Drug Profile
  • CVBT-141B – Drug Profile
  • diperoxochloric acid – Drug Profile
  • EBC-1013 – Drug Profile
  • ENERGIF-703 – Drug Profile
  • EscharEx – Drug Profile
  • EscharEx Second Generation – Drug Profile
  • FGF-1 – Drug Profile
  • molgramostim – Drug Profile
  • NLP-328 – Drug Profile
  • P-128 – Drug Profile
  • ropocamptide – Drug Profile
  • sodium hypochlorite – Drug Profile
  • Stem Cell Therapy for Venous Leg Ulcers – Drug Profile
  • TR-987 – Drug Profile

Dormant Projects

Discontinued Products

Product Development Milestones

Featured News & Press Releases

  • Jan 24, 2022: MediWound announces positive topline results from its U.S. phase 2 trial of EscharEx for debridement of chronic wounds
  • Oct 25, 2021: Promore Pharma announces that scientific article has been published on clinical study results with ropocamptide for venous leg ulcers
  • Oct 19, 2021: From chronic to curable RHEACELL is developing a novel cell-therapy agent for the treatment of chronic venous ulcers
  • Jul 28, 2021: MediWound announces positive outcome of interim assessment for its EscharEx U.S. phase 2 adaptive design study
  • Jul 09, 2021: MediWound announces peer-reviewed paper detailing Escharex phase 2 randomized control trial results published in the online Wound Repair and Regeneration Journal
  • Jun 09, 2021: MediWound completes patient enrollment for interim assessment of its U.S. EscharEx phase 2 adaptive design study
  • Apr 22, 2021: MediWound enrolls first patient in phase 2 pharmacology study of EscharEx
  • Jan 11, 2021: MediWound provides progress update on its EscharEx clinical development program

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ezqmco

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900